Previous Close | 17.50 |
Open | 17.50 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 145.00 |
Expire Date | 2024-08-16 |
Day's Range | 17.50 - 17.50 |
Contract Range | N/A |
Volume | |
Open Interest | 6 |
Beigene's (BGNE) shares surge 32% in a month due to the label expansion of one of its key oncology drugs, Tevimbra, to treat three NSCLC indications, including first- and second-line use, in the EU.
SAN MATEO, Calif., May 14, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data from its hematology portfolio and pipeline at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain, June 13-16, 2024. BeiGene has 28 abstracts accepted at EHA2024, with four scheduled for oral presentations.
A week ago, BeiGene, Ltd. ( NASDAQ:BGNE ) came out with a strong set of quarterly numbers that could potentially lead...